Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

Cancer: Starving sarcomas into submission A drug that inhibits blood vessel growth offers a potentially promising treatment for a class of tumors with a poor prognosis. Sarcomas form in bone and connective tissue, and patients with advanced disease have a five-year survival rate of less than 10%. Re...

Full description

Bibliographic Details
Main Authors:	Zhichao Liao, Feng Li, Chao Zhang, Lei Zhu, Yehui Shi, Gang Zhao, Xu Bai, Shafat Hassan, Xinyue Liu, Ting Li, Peipei Xing, Jun Zhao, Jin Zhang, Ruwei Xing, Sheng Teng, Yun Yang, Kexin Chen, Jilong Yang
Format:	Article
Language:	English
Published:	Nature Publishing Group 2019-02-01
Series:	Experimental and Molecular Medicine
Online Access:	https://doi.org/10.1038/s12276-019-0221-7

Similar Items

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
by: Zhichao Liao, et al.
Published: (2020-05-01)

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
by: Jia Lu, et al.
Published: (2022-06-01)

Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study
by: Zhichao Liao, et al.
Published: (2024-03-01)

Clinicopathologic features, prognostic factors, and outcomes of visceral sarcomas: A retrospective 12-year single-center study
by: Songwei Yang, et al.
Published: (2022-11-01)

BRAF mutation and its inhibitors in sarcoma treatment
by: Haotian Liu, et al.
Published: (2020-07-01)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
by: Jiaming Xu, et al.
Published: (2020-11-01)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
by: Jiaqiang Wang, et al.
Published: (2023-11-01)

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
by: Tian Z, et al.
Published: (2019-06-01)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
by: Zhaolun Cai, et al.
Published: (2019-06-01)

Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting
by: Jilong Yang, et al.
Published: (2022-10-01)

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution
by: Wang Y, et al.
Published: (2019-04-01)

Clinical observation of apatinib in the treatment of metastatic colorectal cancer
by: CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun
Published: (2021-12-01)

Pan-Soft Tissue Sarcoma Analysis of the Incidence, Survival, and Metastasis: A Population-Based Study Focusing on Distant Metastasis and Lymph Node Metastasis
by: Haotian Liu, et al.
Published: (2022-07-01)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01)

First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
by: Xiaofeng Chen, et al.
Published: (2024-03-01)

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion
by: Lingying Zhao, et al.
Published: (2022-05-01)

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
by: Yong-An Song, et al.
Published: (2019-05-01)

A Case Report of Primary Pulmonary Synovial Sarcoma with Postoperative Multiple Metastases Treated with Apatinib
by: Di ZHANG, et al.
Published: (2018-11-01)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
by: Taojun Gong, et al.
Published: (2022-11-01)

Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis.
by: Thomas K Kilvaer, et al.
Published: (2010-01-01)

Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
by: Zuoyao Long, et al.
Published: (2021-03-01)

Roles of low-density lipoprotein receptor-related protein 1 in tumors
by: Peipei Xing, et al.
Published: (2016-01-01)

Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature Review
by: Lin Y, et al.
Published: (2022-06-01)

Histone deacetylase 6 in cancer
by: Ting Li, et al.
Published: (2018-09-01)

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
by: Lu Xie, et al.
Published: (2018-04-01)

The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution
by: Wang Y, et al.
Published: (2018-12-01)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022-06-01)

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
by: Wu-tong Ju, et al.
Published: (2022-09-01)

A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas
by: Yan Zhou, et al.
Published: (2023-11-01)

Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature Review
by: Mengxi Zhang, et al.
Published: (2019-11-01)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
by: Lin-Quan Tang, et al.
Published: (2023-03-01)

A study protocol for an open‐label, single‐arm, single‐center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma
by: Huiying Huang, et al.
Published: (2024-02-01)

Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience
by: Lu Xie, et al.
Published: (2021-07-01)

Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
by: Ningning Li, et al.
Published: (2021-02-01)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
by: Qingyuan Zhang, et al.
Published: (2022-10-01)

A Case Report of Apatinib Mesylate in Treatment of Advanced Alveolar Soft Part Sarcoma with Multiple Metastases
by: ZHU Xianmin, et al.
Published: (2022-06-01)

A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma
by: Chao Zhang, et al.
Published: (2022-11-01)

Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell
by: Manping Huang, et al.
Published: (2018-11-01)

Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
by: Zhichao Tian, et al.
Published: (2021-10-01)

Apatinib for molecular targeted therapy in tumor
by: Zhang H
Published: (2015-11-01)